Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

Worldwide burden of cervical cancer in 2008

2011 • 1,083 citations

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 654 citations

Cervicovaginal Human Papillomavirus Infection in Human Immunodeficiency Virus-1 (HIV)-Positive and High-Risk HIV-Negative Women

1999 • 544 citations

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

2006 • 480 citations

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 472 citations

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

2007 • 456 citations

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

2009 • 347 citations

Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.

1995 • 283 citations

Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

2003 • 236 citations

Monophosphoryl Lipid A as an Adjuvant

1995 • 214 citations

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

2009 • 196 citations

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

2008 • 172 citations

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

2011 • 155 citations

HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study

2006 • 142 citations

Human Papillomavirus Infection and Cervical Disease in Human Immunodeficiency Virus-1–Infected Women

2008 • 139 citations

Human Papillomavirus Infection and Cervical Cytology in HIV‐Infected and HIV‐Uninfected Rwandan Women

2009 • 99 citations

Association of Oncogenic and Nononcogenic Human Papillomavirus With HIV Incidence

2009 • 69 citations

Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions.

2009 • 64 citations

Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening

2008 • 61 citations

Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: A case-control study

2010 • 59 citations

Deleted Work

1955 • 0 citations

Cited By (0)

No citing papers found in database